Media Center

Novartis Q1 Results 2015

Basel, April 23, 2015 - Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Our focus on execution has resulted in a strong operational performance. We have completed the GSK and Lilly transactions and innovation continues to be strong. We had three approvals in Oncology, FDA priority review for LCZ696, Zarxio became the first biosimilar approved under the new pathway in the US and we launched Cosentyx globally. We are on track to deliver our full-year guidance."

  • Continuing operations1 saw sales, core2 operating income and core EPS grow (cc2) in Q1
    • Net sales were USD 11.9 billion (-7%, +3% cc)2
    • Operating income was USD 2.8 billion (-1%, +15% cc)
    • Core operating income (-4%, +9% cc) grew faster than sales (cc), resulting in core margin of 30.6%
    • Core EPS was USD 1.33 (-1%, +11% cc))
    • Further strengthening of USD impacted sales by -10% and core operating income by -13%
    • Free cash flow2 increased 27% to USD 1.5 billion
  • For total Group, Q1 divestments resulted in exceptional operating income gains totaling USD 12.8 billion and net income gains of USD 10.8 billion
  • Strong progress on innovation continued in Q1
    • Three approvals in Oncology: Jakavi in polycythemia vera (EU), Farydak in multiple myeloma (US) and Jadenu for chronic iron overload (US)
    • LCZ696 granted FDA priority review and CHMP accelerated assessment in heart failure
    • Positive trials on Cosentyx in psoriasis showing superiority to Stelara®, sustained two-year efficacy
    • Sandoz received FDA approval for first biosimilar Zarxio and in April for first substitutable generic version of Copaxone® 20mg one-time-daily injection, Glatopa
  • Growth Products3 and Emerging Growth Markets3 continued to drive performance in Q4
    • Growth Products grew 14% (USD) to USD 4.7 billion, or 32% of Group net sales
    • Strong performance in Emerging Growth Markets (+12% cc)
  • Portfolio rejuvenation continued in Q1, reinforcing growth prospects for continuing operations
    • Growth Products3 grew 15% (USD) to USD 3.7 billion, or 31% of net sales
    • Strong performance in Emerging Growth Markets3 (+12% cc)
  • Continued progress in transforming portfolio and increasing productivity
    • Transactions with GSK and Lilly closed on March 2 and January 1, respectively; divestment of influenza Vaccines business to CSL expected to be completed in H2 2015
    • For continuing operations, core margin improved (+1.7 percentage points cc) mainly due to ongoing productivity initiatives
  • Outlook 2015 for continuing operations confirmed
    • Net sales expected to grow mid-single digit (cc); core operating income expected to grow ahead of sales at a high-single digit rate (cc) (cc)

Read the media release (PDF)


1Refers to continuing operations. Continuing operations are defined on page 34 of the Condensed Interim Financial Report. Total Group results include exceptional divestment gains and other operational results of discontinued operations. See page 4. of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
2 Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42
3 Growth Products are defined on page 2 and Emerging Growth Markets on page 6